Acne conglobata
Methodology & AI Transparency ⓘ
Acne conglobata Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Acne conglobata uses ICD-10 L70.1 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Clinicians assessing Acne conglobata focus on cutaneous immune skewing in Acne conglobata (L70.1: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Acne conglobata: maintaining Affected Body Surface in Acne conglobata (L70.1: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L70.1).
Ask our AI Specialists anything about Acne conglobata
What Is Acne conglobata?
Recognized across U.S. clinical coding as L70.1 (Skin & Dermatology), Acne conglobata is evaluated via clinical dermatologic lesion in Acne conglobata (L70.1: morphology exam) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Acne conglobata (L70.1) features cutaneous immune skewing in Acne conglobata (L70.1: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against Fasting Lipids & in Acne conglobata (L70.1: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Acne conglobata (L70.1): recurrent flares triggered in Acne conglobata (L70.1: by UV exposure,)
- • Secondary Acne conglobata clinical sign: persistent erythematous plaques, in Acne conglobata (L70.1: scaly patches, pruritic)
- • Symptom flares in Acne conglobata correlating with Affected Body Surface in Acne conglobata (L70.1: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L70.1)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Acne conglobata (L70.1: morphology exam) evaluation (L70.1)
Acne conglobata Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L70.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Acne conglobata (L70.1: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L70.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Acne conglobata (L70.1: ALT (if systemic) | Within baseline reference limits (L70.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Acne conglobata (L70.1: & hs-CRP) | 25(OH)D 40–65 ng/mL (L70.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Acne conglobata
Treatment selection for Acne conglobata depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acne conglobata)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Janus kinase inhibitors and side effects of acne in dermatologic: What a 11,396-Participant Study Found Conclusions: There are higher rates of acne following treatment with JAK inhibitors for dermatologic indications, particularly with longer durations and larger dosages. The Journal of dermatological treatment • 2024-12-15 • Meta-Analysis | N = 11,396 | 94/100 | PMID 39218446 ↗ |
| New Insights on Gold-standard blind, vehicle-controlled, multicenter comparison of two 0.025%: What a 271-Participant Study Found The commercially-available 0.025% tretinoin cream and the 0.025% tretinoin cream containing polyolprepolymer-2 demonstrated comparable real-world benefits and safety. Journal of the American Academy of Dermatology • 1998-04-15 • Randomized Controlled Trial | N = 271 | 93/100 | PMID 9555823 ↗ |
| New Insights on Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily: What a 551-Participant Study Found Conclusions: Tretinoin 0.05% lotion was significantly more effective than vehicle in achieving treatment success and reducing inflammatory and noninflammatory lesions in adult females with moderate acne, with notable... Journal of drugs in dermatology : JDD • 2019-11-01 • Randomized Controlled Trial | N = 551 | 93/100 | PMID 31741360 ↗ |
Acne conglobata Patient Community & “People Like Me” Threads
Filter Acne conglobata community threads and patient logs by age, biological sex, dosage, and treatment duration.